Report #2884144

Received Feb 4, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 23 yrs
State: IN
Recovered: Unknown
Vaccinated: Jan 20, 2026
Onset: Jan 20, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (ENGERIX-B)	GLAXOSMITHKLINE BIOLOGICALS	1	5F244	—

Symptoms (1)

Underdose

Symptom narrative

Administration of Less than the Recommended Dose of Engerix-B in Adults; Administration of Less than the Recommended Dose of Engerix-B in Adults; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 23-year-old female patient who received HBV (Engerix B pediatric) (batch number 5F244, expiry date 09-SEP-2027) for prophylaxis. On 20-JAN-2026, the patient received the 1st dose of Engerix B pediatric. On 20-JAN-2026, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: Administration of Less than the Recommended Dose of Engerix-B in Adults) and underdose (Verbatim: Administration of Less than the Recommended Dose of Engerix-B in Adults). The outcome of the adult use of a child product and underdose were not applicable. Additional Information: GSK Receipt Date: 23-JAN-2026 The vaccine administration facility was the same as the primary reporter.